You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 136 No. 7, July 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  The Cutting Edge: Challenges in Medical and Surgical Therapeutics
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatology, Other
 •Alert me on articles by topic

A Case of Angiolymphoid Hyperplasia With Eosinophilia Treated With Intralesional Interferon Alfa-2a

Philip D. Shenefelt, MD; Margaret Rinker, MD; Stephanie Caradonna, MD
From the University of South Florida, Tampa (Drs Shenefelt and Rinker), and University of Florida, Gainesville (Dr Caradonna)

Arch Dermatol. 2000;136:837-839.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF A CASE

A 52-year-old white woman presented with a 1-year history of pruritic, erythematous nodules on her right ear and preauricular area (Figure 1). The lesions had a tendency to bleed after minor trauma and had been gradually increasing in size and number. A biopsy was performed, and the findings were consistent with the diagnosis of angiolymphoid hyperplasia with eosinophilia (ALHE).


 
Figure appears in full text version.
Figure 1. Angiolymphoid hyperplasia with eosinophilia on the patient's right ear before intralesional interferon alfa-2a therapy.


The patient was initially treated with a combination of intralesional triamcinolone acetonide and cryosurgery, at 1- to 4-month intervals. The triamcinolone acetonide therapy was started with 1 to 2 mL intralesionally at 5 mg/mL, and the concentration was gradually increased to 20 mg/mL. The patient's response was variable, with improvement seen at some visits and worsening noted at others. After 11/2 years, and . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.